Roche: 9% sales growth in Q3

(CercleFinance.com) - Roche today announced its Q3 2024 results.
Group sales rose by 6% at constant exchange rates in the first nine months to 45bn CHF. Excluding products related to COVID-19, sales rose by 8%. Group sales rose by 9% in Q3.

Pharmaceuticals Division sales rose by 7% in the first nine months. Strong core business growth of 9% was driven by continued strong demand for drugs to treat serious diseases.

Diagnostics Division sales rose by 5% in the first nine months, while core business grew by 8% due to increased demand for immunodiagnostic, pathology and molecular solutions.

We have made significant progress in our pharmaceuticals portfolio with five major drug approvals, three positive Phase III results and two acquisitions, rejoices Thomas Schinecker, Roche's CEO before announcing confirmation of its outlook for 2024.

Roche expects Group sales to grow in the mid-single-digit range. Basic earnings per share should grow in the high single-digit range, excluding the impact of the resolution of tax disputes in 2023.

Roche plans to further increase its dividend in Swiss francs.


Copyright (c) 2024 CercleFinance.com. All rights reserved.